• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Recent advances in anaplastic thyroid cancer management
Curr Opin Endocrinol Diabetes Obes. 2023 Jul 7. doi: 10.1097/MED.0000000000000823. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: To summarize recent developments in the diagnosis and management of patients with anaplastic thyroid cancer (ATC).RECENT FINDINGS: An updated edition of the Classification of Endocrine and Neuroendocrine Tumors was released by the World Health Organization (WHO), in which squamous cell carcinoma of the thyroid are now a subtype of ATC. Broader access to next generation sequencing has allowed better understanding of the molecular mechanisms driving ATC and improved prognostication. BRAF-targete...
Source: Cancer Control - July 6, 2023 Category: Cancer & Oncology Authors: Sarah Hamidi Anastasios Maniakas Source Type: research

Post-mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes
CONCLUSIONS: Based on one study, the use of PMRT in women diagnosed with breast cancer and low-volume axillary disease indicated a reduction in locoregional recurrence and an improvement in survival. There is a need for more research to be conducted using modern-day radiotherapy equipment and methods to support and supplement the review findings.PMID:37327075 | DOI:10.1002/14651858.CD014463.pub2
Source: Cochrane Database of Systematic Reviews - June 16, 2023 Category: General Medicine Authors: Rashmi Verma Mihir Chandarana Jessica Barrett Carmel Anandadas Sreekumar Sundara Rajan Source Type: research

A systematic review of therapeutic strategies in gastroenteropancreatic grade 3 neuroendocrine tumors
CONCLUSION: The latest available data on the epidemiology, diagnosis, molecular changes, and treatment of G3 GEP NET are described. Yet, the level of evidence for treatment recommendations is low, as most studies are retrospective. A treatment algorithm for G3 GEP NET is proposed.PMID:36950274 | PMC:PMC10026121 | DOI:10.1177/17588359231156218
Source: Adv Data - March 23, 2023 Category: Epidemiology Authors: Mauro D Donadio Ângelo B Brito Rachel P Riechelmann Source Type: research

Complete response after neoadjuvant therapy : How certain is the pathology?
Chirurg. 2021 Oct 6. doi: 10.1007/s00104-021-01510-w. Online ahead of print.ABSTRACTHistopathologic evaluation of tumors after neoadjuvant therapy is performed by tumor regression grading (TRG) systems, which reflect the proportion of vital residual primary tumor in relation to the previous total tumor. The World Health Organization (WHO) tumor grading is replaced by TRG in tumor classification. The histopathological work-up of a tumor is based on the criteria of the TNM classification even after neoadjuvant therapy. A uniform TRG does not exist. For various tumors TRGs based on the tumor entity have been established, cons...
Source: Der Chirurg - October 6, 2021 Category: Surgery Authors: Iris Tischoff Andrea Tannapfel Source Type: research

Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer
CONCLUSIONS: In summary, a moderate PFS benefit by including capecitabine was seen only in hormone receptor-positive cancers in metastatic studies. No benefit of capecitabine for pCR was noted overall or in hormone receptor subgroups when included in neoadjuvant therapy. In contrast, the addition of capecitabine in the adjuvant setting led to improved outcomes for OS and DFS in hormone receptor-negative cancer. Future studies should stratify by hormone receptor and triple-negative breast cancer (TNBC) status to clarify the differential effects of capecitabine in these subgroups across all treatment scenarios, to optimally ...
Source: Cochrane Database of Systematic Reviews - May 26, 2021 Category: General Medicine Authors: Siao-Nge Hoon Peter Kh Lau Alison M White Max K Bulsara Patricia D Banks Andrew D Redfern Source Type: research

Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
CONCLUSIONS: In the neoadjuvant setting, there is high- to low-certainty evidence of equivalent outcomes for the sequence in which taxanes are delivered. In the adjuvant setting, none of the studies reported on overall survival or disease-free survival. In most institutions, standard practice would be to deliver anthracycline followed by taxane, and currently available data do not support a change in this practice. We wait for the full-text publication of a relevant neoadjuvant study for women with HER2-negative breast cancer for inclusion in an update of this review. PMID: 30776132 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - February 18, 2019 Category: General Medicine Authors: Zaheed M, Wilcken N, Willson ML, O'Connell DL, Goodwin A Tags: Cochrane Database Syst Rev Source Type: research

Exercise for women receiving adjuvant therapy for breast cancer.
CONCLUSIONS: Exercise during adjuvant treatment for breast cancer can be regarded as a supportive self care intervention that probably results in less fatigue, improved physical fitness, and little or no difference in cancer-specific quality of life and depression. Exercise may also slightly improve cancer site-specific quality of life and cognitive function, while it may result in little or no difference in health-related quality of life. This review is based on trials with a considerable degree of clinical heterogeneity regarding adjuvant cancer treatments and exercise interventions. Due to the difficulty of blinding exe...
Source: Cochrane Database of Systematic Reviews - September 20, 2016 Category: Journals (General) Authors: Furmaniak AC, Menig M, Markes MH Tags: Cochrane Database Syst Rev Source Type: research